

# Esther Masih-Khan

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5875112/publications.pdf>

Version: 2024-02-01

25  
papers

213  
citations

1478505

6  
h-index

1058476

14  
g-index

25  
all docs

25  
docs citations

25  
times ranked

459  
citing authors

#	ARTICLE	IF	CITATIONS
1	Second Autologous Stem Cell Transplantation as Salvage Therapy for Multiple Myeloma: Impact on Progression-Free and Overall Survival. <i>Biology of Blood and Marrow Transplantation</i> , 2012, 18, 773-779.	2.0	108
2	Secondary primary malignancies during the lenalidomide+dexamethasone regimen in relapsed/refractory multiple myeloma patients. <i>Cancer Medicine</i> , 2017, 6, 3-11.	2.8	24
3	Toxicity and survival outcomes of autologous stem cell transplant in multiple myeloma patients with renal insufficiency: an institutional comparison between two eras. <i>Bone Marrow Transplantation</i> , 2020, 55, 578-585.	2.4	17
4	Cyclophosphamide and Bortezomib With Prednisone or Dexamethasone for the Treatment of Relapsed and Refractory Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2016, 16, 387-394.	0.4	11
5	The survival impact of maintenance lenalidomide: an analysis of real-world data from the Canadian Myeloma Research Group national database. <i>Haematologica</i> , 2021, 106, 1733-1736.	3.5	11
6	Real-world outcomes with bortezomib-containing regimens and lenalidomide plus dexamethasone for the treatment of transplant-ineligible multiple myeloma: a multi-institutional report from the Canadian Myeloma Research Group database. <i>British Journal of Haematology</i> , 2021, 193, 532-541.	2.5	9
7	Addition of Cyclophosphamide "On Demand" to Lenalidomide and Corticosteroids in Patients With Relapsed/Refractory Multiple Myeloma: A Retrospective Review of a Single-center Experience. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, e195-e203.	0.4	4
8	Retrospective study of treatment patterns and outcomes post-lenalidomide for multiple myeloma in Canada. <i>European Journal of Haematology</i> , 2021, 107, 416-427.	2.2	4
9	Survival and Outcomes of Newly Diagnosed Multiple Myeloma Patients Stratified by Transplant Status 2007-2018: Retrospective Analysis from the Canadian Myeloma Research Group Database. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2022, 22, 608-617.	0.4	4
10	Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) Induction Therapy For Newly Diagnosed Light Chain Amyloidosis. <i>Blood</i> , 2013, 122, 3231-3231.	1.4	3
11	Pattern of First Relapse in Multiple Myeloma (MM) Patients (Pts) after a Cybord Induction Regimen and Autologous Stem Cell Transplantation (ASCT): Impact of Maintenance Therapy in the Real-World Setting. <i>Blood</i> , 2016, 128, 2137-2137.	1.4	3
12	Efficacy of Daratumumab-Containing Regimens Among Patients With Multiple Myeloma Progressing on Lenalidomide Maintenance: Retrospective Analysis. <i>Frontiers in Oncology</i> , 2022, 12, 826342.	2.8	3
13	Sequential Use of Carfilzomib and Pomalidomide in Relapsed Multiple Myeloma: A Report from the Canadian Myeloma Research Group (CMRG) Database. <i>Current Oncology</i> , 2022, 29, 1575-1582.	2.2	3
14	Outcomes of daratumumab in the treatment of multiple myeloma: A retrospective cohort study from the Canadian Myeloma Research Group Database. <i>British Journal of Haematology</i> , 2022, 198, 93-102.	2.5	3
15	The impact of lenalidomide maintenance on second-line chemotherapy in transplant eligible patients with multiple myeloma. <i>European Journal of Haematology</i> , 2021, 106, 673-681.	2.2	2
16	Real-World Outcomes with Bortezomib-Containing Regimens and Lenalidomide Plus Dexamethasone for the Treatment of Transplant Ineligible MM Patients: A Multi-Institutional Report from the National Myeloma Canada Research Network (MCRN) Database. <i>Blood</i> , 2018, 132, 2008-2008.	1.4	2
17	Supermobilizers with High CD34 + Cell Collection for Autologous Transplant and Impact on Survival Outcomes in Multiple Myeloma. <i>Blood</i> , 2021, 138, 1837-1837.	1.4	1
18	Efficacy of Daratumumab Containing Regimens Post Lenalidomide Maintenance in Transplant Eligible Patients: Real-World Experience from the Canadian Myeloma Research Group Database. <i>Blood</i> , 2020, 136, 26-27.	1.4	1

#	ARTICLE	IF	CITATIONS
19	Fixed duration <i>vs.</i> prolonged duration treatment after first line therapy in patients with systemic light chain amyloidosis. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2022, 29, 23-30.	3.0	0
20	Outcome Of t(4;14) In Multiple Myeloma - Princess Margaret Cancer Centre Experience Over The Last 10 Years. <i>Blood</i> , 2013, 122, 5315-5315.	1.4	0
21	Addition of Cyclophosphamide, on Demand, to Lenalidomide and Corticosteroids in Patients with Relapsed/Refractory Multiple Myeloma, a Retrospective Review of a Single Centre Experience. <i>Blood</i> , 2015, 126, 1842-1842.	1.4	0
22	Salvage Autologous Stem Cell Transplant in Relapsed Myeloma Patients in the Era of Modern Treatment: Is There a Role?. <i>Blood</i> , 2019, 134, 5704-5704.	1.4	0
23	Kinetics of response to first and second line therapies in multiple myeloma: Assessment by both M $\alpha$ spikes and light chains. <i>European Journal of Haematology</i> , 2022, 108, 204-211.	2.2	0
24	Lenalidomide Dosing and Outcomes in Transplant-Ineligible Patients with Newly-Diagnosed Multiple Myeloma: A Multi-Institutional Report from the Canadian Myeloma Research Group (CMRG) Database. <i>Blood</i> , 2021, 138, 4721-4721.	1.4	0
25	Sequential Use of Carfilzomib and Pomalidomide in Relapsed Multiple Myeloma: A Multi-Institutional Report from the Canadian Myeloma Research Group (CMRG) Database. <i>Blood</i> , 2020, 136, 5-7.	1.4	0